BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis ...Middle East

Sustained symptom relief in patients with psoriatic arthritis: Achievement of the stringent ACR50 endpoint was sustained at three years by 53.2% and 55.2% of patients with psoriatic arthritis (PsA) naïve to biologics or who had an inadequate response to, or were intolerant of, tumor...

Hence then, the article about bimzelx bimekizumab bkzx three year data at eular 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis was published today ( Wednesday 11/06/2025 - 07:20 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BIMZELX® (bimekizumab-bkzx) Three-Year Data at EULAR 2025 Showed Lasting Efficacy and Control of Inflammation in Psoriatic Arthritis and Axial Spondyloarthritis )

Also on site :

• Hollywood mourns loss of beloved makeup artist Jasen Kaplan
• Suspected mountain lion attack in Colorado mountains under investigation
• Person falls to death on Boylston Street on New Year’s Eve